Dec 17, 2020
|
PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality RALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of
|
|
Nov 19, 2020
|
Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA’s industry-leading DCT practice RALEIGH, N.C. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the appointment of Isaac Rodriguez-Chavez,
|
|
Nov 04, 2020
|
Net new business of $737.9 million; representing growth of 10.2%; Net book-to-bill of 1.28 excluding reimbursement revenue Net new business of $986.0 million; Net book-to-bill of 1.35 including reimbursement revenue $796.3 million of total revenue; representing growth of 2.0% at actual foreign
|
|
Oct 07, 2020
|
RALEIGH, N.C., Oct. 07, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2020 results after the market closes on Wednesday, November 4, 2020. The Company will also host a conference call on Thursday, November 5, 2020 at 9:00 a.m.
|
|
Oct 06, 2020
|
With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health RALEIGH, N.C., Oct. 06, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today it has been selected by the
|
|
Sep 18, 2020
|
The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc.
|
|
Sep 15, 2020
|
RALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020. “We are delighted that Glen will be joining our Board of Directors. With his
|
|
Aug 06, 2020
|
Net new business of $701.6 million; Net book-to-bill of 1.35 excluding reimbursement revenue Net new business of $1,083.3 million; Net book-to-bill of 1.62 including reimbursement revenue $729.9 million of total revenue; representing a decrease of 4.4% at actual foreign exchange rates and 3.8% on a
|
|
Jul 02, 2020
|
RALEIGH, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020. The Company will also host a conference call on Friday, August 7, 2020 at 9:00 a.m.
|
|
Jun 18, 2020
|
U.S. law requiring clinical research for pediatric oncology treatments goes into effect mid-August 2020 RALEIGH, N.C., June 18, 2020 (GLOBE NEWSWIRE) -- Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration, 1 but none of those drugs were researched
|
|
Jun 12, 2020
|
RALEIGH, N.C., June 12, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service. Users of PRA’s Health Harmony digital platform who
|
|
Apr 30, 2020
|
Net new business of $604.7 million; Net book-to-bill of 1.10 excluding reimbursement revenue Net new business of $955.9 million; Net book-to-bill of 1.32 including reimbursement revenue $783.7 million of total revenue; representing 8.5% growth at actual foreign exchange rates and 9.3% growth on a
|
|
Apr 13, 2020
|
RALEIGH, N.C., April 13, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020. The Company will also host a conference call on Friday, May 1, 2020 at 9:00 a.m.
|
|
Apr 08, 2020
|
Metys COVID-19 Module delivers pharmaceutical market analytics and intelligence quickly through a single access point RALEIGH, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license
|
|
Mar 24, 2020
|
PRA’s Mobile Health Platform delivers virtual solutions for sites and patients enrolled in trials RALEIGH, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced today the expansion of its industry-leading Mobile Health Platform
|
|
Mar 20, 2020
|
Three-tiered, mobile-app driven program tracks individuals’ physical and psychological symptoms from COVID-19 RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative
|
|
Mar 11, 2020
|
Life sciences customers will gain flexibility to build bespoke, fit-for-purpose data assets and strategies to support the development and delivery of life-enhancing drugs RALEIGH, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today a partnership between
|
|
Feb 20, 2020
|
Net new business of $658.9 million in the fourth quarter; Net book-to-bill of 1.21 $800.2 million of revenue in the fourth quarter; 9.7% growth at actual foreign exchange rates and 10.2% growth on a constant currency basis Fourth quarter GAAP net income per diluted share of $1.16 and GAAP net
|
|
Feb 03, 2020
|
RALEIGH, N.C., Feb. 03, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2019 results after the market closes on Thursday, February 20, 2020. The Company will also host a conference call on Friday, February 21, 2020 at 9:00 a.m.
|
|
Oct 30, 2019
|
Net new business of $669.4 million; Net book-to-bill of 1.22 $780.7 million of total revenue; representing 8.8% growth at actual foreign exchange rates and 9.7% growth on a constant currency basis GAAP net income per diluted share of $1.25 and GAAP net income of $83.0 million Adjusted net income
|
|
Oct 09, 2019
|
RALEIGH, N.C., Oct. 09, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2019 results after the market closes on Wednesday, October 30, 2019. The Company will also host a conference call on Thursday, October 31, 2019 at 9:00 a.m.
|
|
Sep 18, 2019
|
The first of its kind, Metys(TM) delivers accurate, reliable data quickly through a single access point RALEIGH, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys ™ (pronounced
|
|
Sep 04, 2019
|
RALEIGH, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock. KKR PRA Investors L.P. (the “Selling Stockholder”), has agreed to sell an aggregate
|
|
Sep 03, 2019
|
RALEIGH, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that its Board of Directors (the “Board”) has authorized a $500 million share repurchase program, effective immediately. Under the program, the Company is authorized to
|
|
Sep 03, 2019
|
RALEIGH, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that KKR PRA Investors L.P. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering 6,666,684 shares of common stock of the Company
|
|
Aug 19, 2019
|
RALEIGH, N.C., Aug. 19, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, the company’s data solutions division, has expanded its global data services by entering into a strategic partnership with Close-Up International , a leading Latin
|
|
Jul 31, 2019
|
Net new business of $670.7 million; Net book-to-bill of 1.24 $763.3 million of total revenue; representing 5.6% growth at actual foreign exchange rates and 6.8% growth on a constant currency basis GAAP net income per diluted share of $0.62 and GAAP net income of $41.1 million Adjusted net income
|
|
Jul 11, 2019
|
RALEIGH, N.C. , July 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 9, 2019 by PRA Health Sciences, Inc. (NASDAQ: PRAH), please note that in the second paragraph of the release, the conference call ID and replay ID should read "6295812" and not "1876878" as
|
|
Jul 09, 2019
|
RALEIGH, N.C., July 09, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2019 results after the market closes on Wednesday, July 31, 2019. The Company will also host a conference call on Thursday, August 1, 2019 at 9:00 a.m.
|
|
May 14, 2019
|
RALEIGH, N.C., May 14, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. is pleased to announce it has received an array of awards and recognition during the first months of 2019. On Saturday, May 4, PRA was recognized as the Clinical Research Company of the Year – the Americas by PharmaTimes .
|
|
May 01, 2019
|
Net new business of $664.6 million; Net book-to-bill of 1.27 $722.0 million of total revenue; representing 2.9% growth at actual foreign exchange rates and 4.4% growth on a constant currency basis GAAP net income per diluted share of $0.66 and GAAP net income of $44.1 million Adjusted net income
|
|
Apr 09, 2019
|
RALEIGH, N.C. , April 09, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2019 results after the market closes on Wednesday, May 1, 2019 . The Company will also host a conference call on Thursday, May 2, 2019 at 9:00 a.m.
|
|
Apr 08, 2019
|
RALEIGH, N.C. , April 08, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. is pleased to announce it has won a 2019 CRO Leadership Award in the following categories: Capabilities (Overall, Big Pharma, Small Pharma) Compatibility (Overall, Big Pharma, Small Pharma) Expertise (Small Pharma) Quality
|
|
Mar 07, 2019
|
BLUE BELL, Pa. , March 07, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences is delighted to be included as the only CRO on the Philadelphia Inquirer’s list of Top Workplaces for 2019. The best employers around the country are annually recognized for their commitment to developing and sustaining a
|
|
Feb 27, 2019
|
Net new business of $667.3 million in the fourth quarter; Net book-to-bill of 1.30 $729.6 million of revenue in the fourth quarter; 11.2% growth at actual foreign exchange rates and 12.0% growth on a constant currency basis Fourth quarter GAAP net income per diluted share of $1.07 and GAAP net
|
|
Feb 25, 2019
|
RALEIGH, N.C , Feb. 25, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences and the non-profit Center for Information and Study on Clinical Research Participation (CISCRP) are pleased to announce that they are collaborating to prepare and deliver Trial Results Summaries to study volunteers.
|
|
Feb 04, 2019
|
RALEIGH, N.C. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2018 results after the market closes on Wednesday, February 27, 2019 . The Company will also host a conference call on Thursday, February 28, 2019 at 9:00 a.m.
|
|
Nov 27, 2018
|
RALEIGH, N.C. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce the launch of its new Pediatric Site Network (PSN). PSN is a series of key pediatric research centers around the world which will allow PRA to improve pediatric clinical development and enhance access
|
|
Nov 21, 2018
|
RALEIGH, N.C. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce the launch of its new Pediatric Site Network (PSN). PSN is a series of key pediatric research centers around the world which will allow PRA to improve pediatric clinical development and enhance access
|
|
Oct 31, 2018
|
Net new business of $657.2 million ; Net book-to-bill of 1.28 $717.6 million of revenue; 23.3% growth at actual foreign exchange rates and 24.0% growth on a constant currency basis $572.9 million of revenue excluding the impact of ASC 606; 15.8% growth at actual foreign exchange rates; 16.3% growth
|
|
Sep 25, 2018
|
RALEIGH, N.C. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter results after the market closes on Wednesday, October 31, 2018 . The Company will also host a conference call on Thursday, November 1, 2018 at 9:00 a.m.
|
|
Aug 07, 2018
|
RALEIGH, N.C. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock. An affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co.
|
|
Aug 06, 2018
|
RALEIGH, N.C. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering
|
|
Aug 01, 2018
|
Net new business of $670.0 million ; Net book-to-bill of 1.30 $722.8 million of revenue; 35.4% growth at actual foreign exchange rates and 34.2% growth on a constant currency basis $575.0 million of revenue excluding the impact of ASC 606; 25.6% actual growth and 12.9% organic growth at actual
|
|
Jul 12, 2018
|
RALEIGH, N.C. , July 12, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter results after the market closes on Wednesday, August 1, 2018 . The Company will also host a conference call on Thursday, August 2, 2018 at 9:00 a.m.
|
|
May 24, 2018
|
RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award.
|
|
May 03, 2018
|
|
|
Apr 25, 2018
|
RALEIGH, N.C. , April 25, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced that Linda Baddour , Executive Vice President and Chief Financial Officer will retire from her position as CFO, effective May 1 , 2018. Ms. Baddour will remain as Executive Vice President of
|
|
Apr 25, 2018
|
|
|
Apr 12, 2018
|
RALEIGH, N.C. , April 12, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2018 results after the market closes on Wednesday, April 25, 2018 . The Company will also host a conference call on Thursday, April 26, 2018 at 9:00 a.m.
|
|
Mar 14, 2018
|
RALEIGH, N.C. , March 14, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it has won a 2018 CRO Phase IV Leadership Award (Overall, Big Pharma). For the 2018 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard
|
|
Mar 06, 2018
|
RALEIGH, N.C. , March 06, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is honored to once again be named Best CRO in Asia . PRA received this recognition at the Phar-East Pharma and Biotech Festival (formally known as BioPharma Asia).
|
|
Feb 21, 2018
|
Net new business of $647.3 million in the fourth quarter; Net book-to-bill of 1.30 $568.8 million of service revenue in the fourth quarter; 37.5% actual growth and 20.2% organic growth at actual foreign exchange rates and 35.9% growth and 18.6% organic growth on a constant currency basis compared
|
|
Feb 12, 2018
|
RALEIGH, N.C. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce that it has joined IMPACT2030 as a collaborating partner. IMPACT2030 is a coalition of businesses working in partnership to help achieve the United Nations’ Sustainable Development Goals
|
|
Jan 24, 2018
|
RALEIGH, N.C. , Jan. 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2017 results after the market closes on Wednesday, February 21, 2018 . The Company will also host a conference call on Thursday, February 22, 2018 at 9:00 a.m.
|
|
Jan 16, 2018
|
RALEIGH, N.C. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce the opening of a new clinic in Salt Lake City, Utah . The new facility will offer full service early stage clinical research capabilities for healthy participants and specialized patient
|
|
Oct 25, 2017
|
Net new business of $598.5 million ; Net book-to-bill of 1.26 $494.6 million of service revenue; 23.7% actual growth and 18.9% organic growth at actual foreign exchange rates and 23.0% growth and 18.2% organic growth on a constant currency basis GAAP Net Income per diluted share was $0.73 and GAAP
|
|
Oct 09, 2017
|
RALEIGH, N.C. , Oct. 09, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2017 results after the market closes on Wednesday, October 25, 2017 . The Company will also host a conference call on Thursday, October 26, 2017 at 8:00 a.m.
|
|
Aug 14, 2017
|
RALEIGH, N.C. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Alexander G. Dickinson to the Board of Directors of the Company. “We are pleased that Alex will be joining our Board of Directors. Alex’s background in technology and
|
|
Aug 09, 2017
|
RALEIGH, N.C. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock. Certain of the Company’s stockholders, including an affiliate of, or a fund sponsored
|
|
Aug 08, 2017
|
RALEIGH, N.C. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders, including an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholders”), intend to offer for sale in an
|
|
Aug 07, 2017
|
Net new business of $603.2 million ; Net book-to-bill of 1.32 $457.9 million of service revenue; 16.2% growth at actual foreign exchange rates and 16.5% constant currency growth GAAP Net Income per diluted share was $0.45 and GAAP Net Income was $29.5 million Adjusted Net Income per diluted
|
|
Aug 07, 2017
|
Enters into definitive agreement to acquire Symphony Health Solutions for upfront cash payment of $ 530 million Strengthens commitment to patient care through enhanced real world evidence based solutions Empowers vision for a more agile, flexible, and adaptive way of conducting clinical research
|
|
Jul 25, 2017
|
RALEIGH, N.C. , July 25, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter results after the market closes on Monday, August 7, 2017 . The Company will also host a conference call on Tuesday, August 8 at 9:00 a.m.
|
|
Jun 19, 2017
|
RALEIGH, N.C. , June 19, 2017 (GLOBE NEWSWIRE) -- As part of its new Center for Pediatric Clinical Development initiative, PRA Health Sciences is pleased to announce its partnership with Jumo. Jumo is an award-winning provider of educational health care information and resources for children,
|
|
May 22, 2017
|
RALEIGH, N.C., May 22, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. , (PRA) (NASDAQ:PRAH) is pleased to announce that for the fourth consecutive year it was recognized as the International Clinical Research Company of the Year. PRA received the award at a PharmaTimes ceremony in London.
|
|
May 04, 2017
|
RALEIGH, N.C , May 04, 2017 (GLOBE NEWSWIRE) -- It is a little known fact that 70% of medicines given to children have been studied only in adults. As a result, most drugs used to treat diseases in children are used off-label. While there are pediatric clinical trial regulations in place, testing
|
|
May 02, 2017
|
RALEIGH, N.C., May 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (PRA) (NASDAQ:PRAH) is pleased to announce that it was once again recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in
|
|
Apr 25, 2017
|
Net new business of $564.8 million in the first quarter; Net book-to-bill of 1.32 $427.1 million of service revenue in the first quarter; 14.7% growth at actual foreign exchange rates and 15.1% constant currency growth compared to the first quarter of 2016 First quarter GAAP Net Income per diluted
|
|
Apr 17, 2017
|
RALEIGH, N.C. , April 17, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2017 results after the market closes on Tuesday, April 25, 2017 . The Company will also host a conference call on Wednesday, April 26, 2017 at 9:00 a.m.
|
|
Mar 27, 2017
|
RALEIGH, N.C. , March 27, 2017 (GLOBE NEWSWIRE) -- For the second year in a row, PRA Health Sciences (PRA) (NASDAQ:PRAH), a leading global contract research organization, has been awarded a Top Workplaces honor by Philly.com. “We are honored to once again receive this recognition,” said Tami Klerr
|
|
Feb 22, 2017
|
Net new business of $587.3 million in the fourth quarter; Net book-to-bill of 1.42 $413.6 million of service revenue in the fourth quarter; 14.2% growth at actual foreign exchange rates and 14.6% constant currency growth compared to the fourth quarter of 2015 Fourth quarter GAAP Net Income per
|
|
Feb 15, 2017
|
Osaka, Japan, February 15, 2017 and Raleigh, N.C., February 15, 2017 – PRA Health Sciences, Inc. ( NASDAQ: PRAH ,“PRA”) and Takeda Pharmaceutical Company Limited ( TSE: 4502 , “Takeda”) announced today that they have agreed to a new partnership to expand their global relationship initially
|
|
Feb 02, 2017
|
RALEIGH, N.C. , Feb. 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2016 results and issue 2017 guidance after the market closes on Wednesday, February 22, 2017 . The Company will also host a conference call on Thursday, February
|
|
Nov 10, 2016
|
RALEIGH, N.C. , Nov. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that one of its stockholders, consisting of an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholder”), intends to offer for sale in an
|
|
Nov 02, 2016
|
$399.8 million of service revenue in the third quarter; 16.0% constant currency growth compared to the third quarter of 2015 Third quarter GAAP Net Income per diluted share increased 32.4% to $0.49 per diluted share and GAAP Net Income increased 32.9% to $31.4 million compared to the third
|
|
Oct 10, 2016
|
RALEIGH, N.C. , Oct. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2 . The Company will also host a conference call on Thursday, November 3 at 9:00 a.m.
|
|
Sep 12, 2016
|
Agreement Supports Accelerated, More Efficient Clinical Trial Strategy and Operations OSAKA, Japan & RALEIGH, N.C.--( BUSINESS WIRE )--PRA Health Sciences, Inc. ( NASDAQ: PRAH ) and Takeda Pharmaceutical Company Limited ( TSE: 4502 ) announced today that the companies have entered into a new
|
|
Jul 28, 2016
|
$394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015 Second quarter GAAP Net Income per diluted share increased 200.0% to $0.60 per diluted share and GAAP Net Income increased 211.5% to $38.7 million compared to the second
|
|
Jul 18, 2016
|
RALEIGH, N.C. , July 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter 2016 results after the market closes on Thursday, July 28 . The Company will also host a conference call on Friday, July 29 at 9:00 a.m.
|
|
May 17, 2016
|
RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. , (PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes International Clinical Researcher of
|
|
May 02, 2016
|
RALEIGH, N.C. , May 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering 5,000,000 shares of common stock of the Company
|
|
Apr 27, 2016
|
$372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015 First quarter GAAP Net Loss of $16.0 million or $0.27 per diluted share, which includes $28.9 million of one-time transaction-related costs and a $21.5 million loss from
|
|
Apr 18, 2016
|
RALEIGH, N.C., April 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. , (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in
|
|
Apr 15, 2016
|
RALEIGH, N.C. , April 15, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2016 results after the market closes on Wednesday, April 27, 2016 . The Company will also host a conference call on Thursday, April 28, 2016 at 9:00 a.m.
|
|
Mar 31, 2016
|
RALEIGH, N.C. , March 31, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH), is pleased to announce that it received a “Highly Commended” designation by Vaccine Industry Excellence (ViE) for Best Contract Research Organization . PRA was originally named a finalist in the category
|
|
Mar 21, 2016
|
RALEIGH, N.C. , March 21, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH), a leading global contract research organization, is pleased to announce that it has been awarded a 2016 Top Workplaces honor by Philly.com. The Top Workplaces recognition is based solely on the results of an
|
|
Mar 17, 2016
|
RALEIGH, N.C. , March 17, 2016 (GLOBE NEWSWIRE) -- PRA Holdings, Inc. (“PRA Holdings”), a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA”) (NASDAQ:PRAH), today announced that the previously announced cash tender offer for up to $133,559,000 aggregate principal amount of its outstanding
|
|
Mar 03, 2016
|
RALEIGH, N.C. , March 03, 2016 (GLOBE NEWSWIRE) -- PRA Holdings, Inc. (“PRA Holdings”), a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA”) (NASDAQ:PRAH), today announced the preliminary results of its previously announced cash tender offer for up to $75 million aggregate principal
|
|
Mar 02, 2016
|
RALEIGH, N.C. , March 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering five million shares of common stock of the Company
|
|
Feb 24, 2016
|
$362.3 million of service revenue in the fourth quarter; 15.1% constant currency growth compared to the fourth quarter of 2014 Fourth quarter GAAP Net Income was $28.5 million or $0.45 per diluted share $67.9 million of Adjusted EBITDA in the fourth quarter; 34.2% growth compared to the fourth
|
|
Feb 18, 2016
|
RALEIGH N.C. , Feb. 18, 2016 (GLOBE NEWSWIRE) -- PRA Holdings, Inc. (“PRA Holdings”), a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA”) (NASDAQ: PRAH), today announced that it has commenced a cash tender offer for up to $75 million aggregate principal amount (the “Maximum Tender
|
|
Feb 04, 2016
|
RALEIGH, N.C. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2015 results after the market closes on Wednesday, February 24, 2016 . The Company will also host a conference call on Thursday, February 25, 2016 at 9:00 a.m.
|
|
Dec 07, 2015
|
SHANGHAI, China and RALEIGH, N.C. , Dec. 07, 2015 (GLOBE NEWSWIRE) -- WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and PRA Health Sciences, Inc.
|
|
Nov 02, 2015
|
$345.1 million of service revenue in the third quarter; 12% constant currency growth compared to the third quarter of 2014 $66.6 million of Adjusted EBITDA in the third quarter; 42% growth compared to the third quarter of 2014 Third quarter Adjusted Net Income per share increased 53% to $0.52
|
|
Oct 26, 2015
|
RALEIGH, N.C. , Oct. 26, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce the opening of its brand new, state-of-the-art Bioanalytical Laboratory in Assen, the Netherlands . The 33,000 square foot facility provides 25 percent more space than PRA’s previous
|
|
Oct 16, 2015
|
RALEIGH, N.C. , Oct. 16, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2015 results after the market closes on Monday, November 2, 2015 . The Company will also host a conference call on Tuesday, November 3, 2015 at 9:00 a.m.
|
|
Oct 13, 2015
|
RALEIGH, N.C. , Oct. 13, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Linda S. Grais , M.D. to the Board of Directors of the Company. As a member of the Board of Directors, Dr. Grais will also serve on the Audit Committee.
|
|
Sep 29, 2015
|
RALEIGH, N.C. , Sept. 29, 2015 (GLOBE NEWSWIRE) -- In an effort to accelerate new vaccines to market, PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce its collaboration with Alliance for Multispecialty Research (AMR). This partnership paves the way for a smarter approach to vaccine
|
|
Sep 10, 2015
|
RALEIGH, N.C. , Sept. 10, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH) a leading global contract research organization, is expanding its presence in Pennsylvania . Employees recently relocated from the company's Horsham and Fort Washington facilities to PRA's new modern Class A+
|
|
Jul 27, 2015
|
$336.5 million of service revenue in the second quarter; 12% constant currency growth compared to the second quarter of 2014 $61.3 million of Adjusted EBITDA in the second quarter; 35% growth compared to the second quarter of 2014 Second quarter Adjusted Net Income per share increased 37% to $0.47
|
|
Jul 20, 2015
|
RALEIGH, N.C. , July 20, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH) is looking to hire new talent. To help attract potential employees from around the world, PRA, a leading global contract research organization (CRO), is launching a new Candidate Experience initiative.
|
|
Jul 16, 2015
|
RALEIGH, N.C. , July 16, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) announced today that it has adjusted the start time for its second quarter 2015 financial results conference call on Tuesday, July 28, 2015 . The call will now begin at 8:00 a.m. (ET) .
|
|
Jul 15, 2015
|
RALEIGH, N.C. , July 15, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter 2015 results after the market closes on Monday, July 27, 2015 . The Company will also host a conference call and webcast on Tuesday, July 28, 2015 at 9:00 a.m.
|
|
Jun 15, 2015
|
RALEIGH, N.C. , June 15, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (Nasdaq:PRAH), a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development.
|
|
Jun 08, 2015
|
RALEIGH, N.C. , June 8, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce that it was once again recognized as the Best Clinical Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Cary, North Carolina .
|
|
May 12, 2015
|
RALEIGH, N.C. , May 12, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to sponsor the first meeting of Quality Assurance (QA) experts in Russia . The Russian Regional Research Quality Association (RQA) Forum will facilitate knowledge sharing and the exchange of ideas and opinions in
|
|
May 06, 2015
|
$332.0 million of service revenue in the first quarter; 10% constant currency service revenue growth compared to the first quarter of 2014 $55.7 million of Adjusted EBITDA in the first quarter; 40% growth compared to the first quarter of 2014 First quarter Adjusted Net Income per share increased
|
|
Apr 27, 2015
|
RALEIGH, N.C. , April 27, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce that it was named Clinical Company of the Year at the International Clinical Researcher of the Year award ceremony in London . This is the second year in a row that PRA has won this prestigious
|
|
Apr 17, 2015
|
RALEIGH, N.C. , April 17, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (Nasdaq:PRAH) will release its first quarter 2015 results after the market closes on Wednesday, May 6, 2015 . The Company will also host a conference call and webcast on Thursday, May 7, 2015 at 9:00 a.m.
|
|
Apr 17, 2015
|
(Thomson Reuters ONE via COMTEX) --RALEIGH, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA), a leading global clinical research organization, is expanding its business in Swansea with the creation of 87 new jobs. The expansion will be supported by £990,060 of business finance
|
|
Mar 30, 2015
|
RALEIGH, N.C. , March 30, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services ( EDS ). These initiatives are being undertaken in response to market demand to
|
|
Feb 18, 2015
|
$323.8 million of service revenue in the fourth quarter; 8% consolidated service revenue growth compared to the fourth quarter of 2013 $50.6 million of Adjusted EBITDA in the fourth quarter; 44% growth compared to the fourth quarter of 2013 Fourth quarter Adjusted Net Income per share increased
|
|
Feb 09, 2015
|
RALEIGH, N.C. , Feb. 9, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (Nasdaq:PRAH) today announced the appointment of Matthew P. Young to the Board of Directors of the Company. As a member of the Board of Directors, Mr. Young will also serve on the Audit Committee.
|
|
Feb 04, 2015
|
RALEIGH, N.C. , Feb. 4, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (Nasdaq:PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18, 2015 . The Company will also host a conference call and webcast on Thursday, February 19, 2015 at
|
|
Dec 12, 2014
|
12 November 2014, Raleigh, N.C. – PRA Health Sciences, Inc. (“PRA”), a leading global contract research organization, today announced the pricing of its initial public offering of 16,976,744 shares of its common stock at $18.00 per share. The shares are expected to begin trading on the Nasdaq
|
|
Sep 08, 2014
|
08 September 2014, Raleigh, N.C. PRA Health Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (“IPO”) of shares of its common stock by PRA Health Sciences and
|
|